多血管床病变与外周动脉疾病患者主要不良心血管事件风险:EUCLID试验二次分析
该研究为EUCLID试验的事后二次分析,纳入13885例外周动脉疾病患者,按单纯PAD、PAD+CAD、PAD+CVD、PAD+CAD+CVD分组。与单纯PAD相比,主要不良心血管事件调整后风险比分别为PAD+CVD 1.34、PAD+CAD 1.65、PAD+CAD+CVD 1.99,下肢血运重建风险亦升高。多血管床病变与急性肢体缺血、大截肢或TIMI大出血风险增加无关。提示对PAD患者应评估其他血管床受累以识别高危人群。
要点
- 与单纯PAD相比,主要不良心血管事件调整后风险比:PAD+CVD 1.34(95%CI 1.15-1.57)、PAD+CAD 1.65(95%CI 1.43-1.91)、PAD+CAD+CVD 1.99(95%CI 1.69-2.34),均P<.001。
- 下肢血运重建调整后风险比:PAD+CAD 1.17(95%CI 1.03-1.34,P=.01)、PAD+CVD 1.17(95%CI 1.02-1.35,P=.02)、PAD+CAD+CVD 1.34(95%CI 1.15-1.57,P<.001)。
- 多血管床病变与急性肢体缺血、大截肢或TIMI大出血风险增加无明确关联。
- 基线构成:单纯PAD 7804例(56.2%),PAD+CAD 2639例(19.0%),PAD+CVD 2049例(14.8%),PAD+CAD+CVD 1393例(10.0%)。
适用人群与场景
- EUCLID试验纳入的13885例外周动脉疾病患者,中位年龄66岁(四分位距60-73岁),女性3888例(28.0%)。
- 按基线合并血管床分为单纯PAD、PAD+CAD、PAD+CVD、PAD+CAD+CVD四组。
研究设计与关键结果
- 研究类型:EUCLID试验的事后二次分析,采用调整Cox比例风险回归模型和意向性治疗分析。
- 主要终点为主要不良心血管事件(心血管死亡、心肌梗死或缺血性卒中)复合终点。
- 与单纯PAD相比,主要不良心血管事件调整后风险比:PAD+CVD 1.34(95%CI 1.15-1.57,P<.001)、PAD+CAD 1.65(95%CI 1.43-1.91,P<.001)、PAD+CAD+CVD 1.99(95%CI 1.69-2.34,P<.001)。
- 下肢血运重建调整后风险比:PAD+CAD 1.17(95%CI 1.03-1.34,P=.01)、PAD+CVD 1.17(95%CI 1.02-1.35,P=.02)、PAD+CAD+CVD 1.34(95%CI 1.15-1.57,P<.001)。
- 急性肢体缺血调整后风险比:PAD+CVD 0.91(95%CI 0.62-1.34,P=.63)、PAD+CAD 0.93(95%CI 0.64-1.34,P=.69)、PAD+CAD+CVD 0.98(95%CI 0.63-1.53,P=.93)。
- 大截肢调整后风险比:PAD+CVD 0.83(95%CI 0.54-1.27,P=.40)、PAD+CAD 0.74(95%CI 0.47-1.16,P=.19)、PAD+CAD+CVD 1.12(95%CI 0.69-1.80,P=.65)。
- TIMI大出血调整后风险比:PAD+CVD 0.98(95%CI 0.66-1.44,P=.91)、PAD+CAD 1.04(95%CI 0.74-1.48,P=.81)、PAD+CAD+CVD 0.96(95%CI 0.62-1.51,P=.88)。
证据类型、等级与局限
- 证据类型:国际多中心随机对照试验EUCLID的事后二次分析。
- EUCLID试验于2012年12月31日至2014年3月7日开展,本二次分析于2017年6月1日至2018年2月5日进行。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对PAD患者应评估是否合并CAD和/或CVD,多血管床受累程度越高,主要不良心血管事件和下肢血运重建风险越高。
- 多血管床病变未显示与急性肢体缺血、大截肢或TIMI大出血风险增加相关。
指南或共识出处
- EUCLID试验(Examining Use of Ticagrelor in Peripheral Artery Disease)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The effect of polyvascular disease on cardiovascular outcomes in the background of peripheral artery disease (PAD) is unclear.
OBJECTIVE: To determine the risk of ischemic events (both cardiac and limb) among patients with PAD and polyvascular disease.
DESIGN, SETTING, AND PARTICIPANTS: In this post hoc secondary analysis of the international Examining Use of Ticagrelor in Peripheral Artery Disease (EUCLID) trial, outcomes were compared among 13 885 enrolled patients with PAD alone, PAD + coronary artery disease (CAD), PAD + cerebrovascular disease (CVD), and PAD + CAD + CVD. Adjusted Cox proportional hazards regression models were implemented to determine the risk associated with polyvascular disease and outcomes, and intention-to-treat analysis was performed. The EUCLID trial was conducted from December 31, 2012, to March 7, 2014; the present post hoc analysis was performed from June 1, 2017, to February 5, 2018.
INTERVENTIONS: EUCLID evaluated ticagrelor vs clopidogrel in preventing major adverse cardiac events (cardiovascular death, myocardial infarction [MI], or ischemic stroke) and major bleeding in patients with PAD.
MAIN OUTCOMES AND MEASURES: The primary end point was a composite of cardiovascular death, MI, or ischemic stroke. Key secondary end points included the individual components of the primary end point and acute limb ischemia leading to hospitalization, major amputation, and lower-extremity revascularization. The primary end point of Thrombolysis in Myocardial Infarction (TIMI) major bleeding was also evaluated.
RESULTS: The EUCLID trial randomized 13 885 patients with a median age of 66 years (interquartile range, 60-73 years), of whom 3888 (28.0%) were women. At baseline, 7804 patients (56.2%) had PAD alone; 2639 (19.0%) had PAD + CAD; 2049 (14.8%) had PAD + CVD; and 1393 (10.0%) had PAD + CAD + CVD. Compared with patients with isolated PAD, the adjusted hazard ratios (aHRs) for major adverse cardiac events were 1.34 (95% CI, 1.15-1.57; P < .001) for PAD + CVD, 1.65 (95% CI, 1.43-1.91; P < .001) for PAD + CAD, and 1.99 (95% CI, 1.69-2.34; P < .001) for PAD + CAD + CVD. The aHRs for lower-extremity revascularization were 1.17 (95% CI, 1.03-1.34; P = .01) for PAD + CAD, 1.17 (95% CI, 1.02-1.35; P = .02) for PAD + CVD, and 1.34 (95% CI, 1.15-1.57; P < .001) for PAD + CAD + CVD. Polyvascular disease was not associated with an increased risk of acute limb ischemia (aHR for PAD + CVD, 0.91; 95% CI, 0.62-1.34, P = .63; PAD + CAD, 0.93; 95% CI, 0.64-1.34, P = .69; and PAD + CAD + CVD, 0.98; 95% CI, 0.63-1.53, P = .93), major amputation (aHR for PAD + CVD, 0.83; 95% CI, 0.54-1.27, P = .40; PAD + CAD, 0.74; 95% CI, 0.47-1.16, P = .19; and PAD + CAD + CVD, 1.12; 95% CI, 0.69-1.80, P = .65), or TIMI major bleeding (PAD + CVD, 0.98; 0.66-1.44, P = .91; PAD + CAD, 1.04; 0.74-1.48, P = .81; and PAD + CAD + CVD, 0.96; 95% CI, 0.62-1.51, P = .88).
CONCLUSIONS AND RELEVANCE: Compared with patients with PAD alone, the risk of major adverse cardiac events and lower-extremity revascularization increased with multiple vascular bed involvement. There was no clear increased risk of bleeding associated with polyvascular disease.
参考来源
- Gutierrez JA, Mulder H, Jones WS, et al. Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial. JAMA Netw Open. 2018. PMID: 30646395. doi:10.1001/jamanetworkopen.2018.5239
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。